在乳腺癌再照射中对正常组织并发症的评估:一个元分析研究
A Amraee1, Y Mokhayeri2, M Gholami3
1Department of Medical Physics, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran. amraee.gelare@yahoo.com.
概括
乳房再照射显示了诸如皮肤纤维化 (47%) 和胸痛 (35%) 等严重并发症的发生率. 这一元分析量化了这些风险,帮助瘤学家在乳腺癌患者的治疗决策.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 医学物理 医学物理
背景情况:
- 越来越多的证据表明,乳腺再辐射是癌症治疗的可行和安全选择.
- 瘤学家对乳腺再辐射表示怀疑,因为担心晚期并发症.
- 乳腺再照射后并发症的流行情况的定量数据对于临床决策至关重要.
研究的目的:
- 为了确定乳房再照射后正常组织并发症的患病率.
- 提供定量数据,以解决瘤学家对乳腺再辐射安全性的担忧.
主要方法:
- 从2000年到2023年,在多个数据库 (EMBASE,MEDLINE,PUBMED,Google Scholar,Cochrane Library) 中进行了全面的文献搜索.
- 在分析中包括了10项主要研究,以估计皮肤疾病,皮肤纤维化和胸痛的患病率.
- 使用Stata 17进行了统计分析,包括异质性评估 (I2指数) 和元回归.
主要成果:
- 接受两阶段放射治疗的患者的平均剂量为100.32 Gy.
- 皮肤纤维化和皮肤疾病的患病率为47% (95%CI为71-22%),具有很高的异质性 (I2 = 96.76%).
- 胸痛的患病率为35% (95% CI 68-8%),同样具有很高的异质性 (I2 = 98.13%).
结论:
- 关于乳腺再辐射疗法的并发症的临床信息仍然有限.
- 这一元分析量化了并发症的患病率,包括皮肤纤维化和胸痛.
- 这些发现旨在帮助放射瘤学家和物理学家在做出有关乳房再辐射的明智决定.
更多相关视频
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.2K
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
239
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:24Healing II: Complications
Complications during healing arise when tissue repair is altered by local or systemic factors. These changes involve abnormal collagen deposition, altered biomechanics, and reduced vascular supply, impairing restoration of normal structure and function.Loss of FunctionScar tissue differs significantly from the original tissue it replaces. In the skin, fibrosis lacks adnexal structures such as hair follicles, sebaceous glands, and sweat glands. Their absence reduces tactile sensitivity, impairs...